Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes

Per Anders Broliden, Inger-Marie Dahl, Robert Hast, Bertil Johansson, Eeva Juvonen, Lars Kjeldsen, Anna Porwit-MacDonald, Malvin Sjoo, Jon-Magnus Tangen, Bertil Uggla, Gunnar Öberg, Eva Hellström-Lindberg

    Forskningsoutput: TidskriftsbidragArtikelVetenskapligPeer review


    "The present study evaluated the combination of antithymocyte globulin (ATG) and cyclosporine A (CsA) in patients with low-risk myelodysplastic syndromes. Twenty patients (17 with refractory anemia and 3 with refractory anemia with excess blasts) received treatment with rabbit-ATG plus CsA. The overall response rate was 30% (6/20); three of the six responders had a complete response. The responses lasted 2-58 months, with two patients still being in complete remission at 42 and 58 months. Short-lasting cytogenetic remissions were achieved in two patients. ATG was poorly tolerated in patients over 70 years of age. Four out of 20 patients progressed to acute myeloid leukemia within a year. We conclude that immunosuppressive treatment may be a therapeutic option for selected patients with myelodysplastic syndrome."
    Sidor (från-till)667-670
    Antal sidor4
    StatusPublicerad - 2006
    MoE-publikationstypA1 Tidskriftsartikel-refererad

    Citera det här